SHP2 Is Required for BCR-ABL1-Induced Hematologic Neoplasia

BCR-ABL1-targeting tyrosine kinase inhibitors (TKIs) have revolutionized treatment of Philadelphia chromosome-positive (Ph(+)) hematologic neoplasms. Nevertheless, acquired TKI resistance remains a major problem in chronic myeloid leukemia (CML), and TKIs are less effective against Ph(+) B-cell acut...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leukemia
Autors principals: Gu, Shengqing, Sayad, Azin, Chan, Gordon, Yang, Wentian, Lu, Zhibin, Virtanen, Carl, Van Etten, Richard A., Neel, Benjamin G.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6005183/
https://ncbi.nlm.nih.gov/pubmed/28804122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2017.250
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars